Erectile Dysfunction (ED) can be caused by physical and/or emotional factors. It has been estimated that the prevalence of ED in U.S. men could be up to 30 million1. ED has been associated with age, with a prevalence of 52% in men aged 40 to 70 years old2. According to a recent study, one out of five men with ED had low testosterone3. Low testosterone is often associated with a loss of sexual desire, as well as a number of other symptoms.
If you have ED, you may have low testosterone. Ask your doctor for a simple blood test which can confirm if your testosterone levels are low. If you do have low testosterone, you and your doctor can discuss whether a once-daily treatment like Testim could help.
Important Safety Information: Testim® is a prescription medicine used to treat hypogonadism, a medical condition that occurs when the body does not make enough testosterone. Only your doctor can decide if Testim is right for you. Testim should not be used by men with known or suspected cancer of the prostate or breast. Testim has not been approved or evaluated for use in women, and must not be used by women. Testosterone may cause fetal harm. Pregnant and nursing women, as well as children, should avoid skin contact with Testim application sites in men. In controlled clinical studies of Testim, the most common side effects reported were redness/irritation at the application site (4%) and above normal red blood cell count (2%).
Indication: Testim® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Important Safety Information: Androgens are contraindicated in men with cancer known or suspected of the breast or prostate. Testim is not indicated for use in women, has not been evaluated for use in women, and must not be used in women. Testosterone may cause fetal harm. Pregnant and nursing women, as well as children, should avoid skin contact with Testim application sites. Geriatric patients treated with androgens may be at greater risk of prostatic hyperplasia and prostatic carcinoma.
Adverse Events: Adverse events reported at a level greater than 1% that were possibly or definitely related to the use of Testim in controlled clinical trials (N=304) across all dose groups were application site reaction (4%) and increase in hematocrit/hemoglobin (2%).